Priyanka Bobbili
Education
Sc.D. and M.S., epidemiology, Harvard T.H. Chan School of Public Health; B.S., chemical and biological engineering, Massachusetts Institute of Technology
Summary of Experience
Dr. Bobbili specializes in the application of statistical methods to the causal analysis of complex longitudinal data. She has a wide range of experience in epidemiology and outcomes research, including studies on causal methods, drug adherence, and comparative effectiveness, particularly in the oncology disease area. Dr. Bobbili has experience designing and conducting studies using large observational and real-world data (RWD) sources to emulate target trials. She has been involved in several studies to support US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory submissions, particularly regulatory-grade real-world studies for new indications, as well as label expansions and historical control studies to help contextualize the results of clinical trials. Her work has been presented at multiple conferences and published in numerous peer-reviewed journals. Prior to joining Analysis Group, Dr. Bobbili served as a research assistant and teaching assistant at the Harvard T. H. Chan School of Public Health.
-
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Clinical Genitourinary Cancer, 2024
2024Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK
-
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Clinical Drug Investigation, 2024
2024Bell CF, Bobbili P, Desai R, Gibbons DC, Drysdale M, DerSarkissian M, Patel V, Birch HJ, Lloyd EJ, Zhang A, Duh MS; N3C consortium
-
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer
Urologic Oncology: Seminars and Original Investigations, 2024
2024Preston MA, Ebrahimi R, Hong A, Bobbili P, Desai R, Duh MS, Gandhi R, Hanson S, Dufour R, Morgans AK
-
Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting
Scientific Reports, 2023
2023Hamy V, Llop C, Yee CW, Garcia-Gancedo L, Maxwell A, Chen WH, Tomlinson R, Bobbili P, Bendelac J, Landry J, DerSarkissian M, Yenikomshian M, Mody EA, Duh MS, Williams R
-
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Leukemia, 2022
2022Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ
-
MPN-435 Overall Survival in Patients With Systemic Mastocytosis With Associated Hematologic Neoplasm Treated With Avapritinib Versus Best Available Therapy
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Reiter A, Gotlib J, Álvarez-Twose I, Radia D, Lübke J, Bobbili P, Wang A, Norregaard C, Dimitrijević S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky I, Perkins C, Sperr W, Sriskandarajah P, Chin A, Sendhil S, Duh MS, Valent P, DeAngelo D
-
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
Annals of Dermatology, 2022
2022Choi GS, Sim WY, Kang H, Huh CH, Lee YW, Shantakumar S, Ho YF, Oh EJ, Duh MS, Cheng WY, Bobbili P, Thompson-Leduc P, Ong G
-
Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study
Allergy, Asthma & Immunology Research, 2022
2022Choi NK, Shantakumar S, Kim MS, Lee CH, Cheng WY, Bobbili P, Yang BR, Lee J, Hinds D, Duh MS, Korves C, Park HW
-
Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease
International Journal of Chronic Obstructive Pulmonary Disease, 2021
2021Mapel DW, Roberts MH, Sama S, Bobbili PJ, Cheng WY, Duh MS, Nguyen C, Thompson-Leduc P, Van Dyke MK, Rothnie KJ, Sundaresan D, Certa JM, Whiting TS, Brown JL, Roblin DW
-
Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer
PLOS One, 2020
2020Bobbili P, Ryan K, DerSarkissian M, Dua A, Yee C, Duh MS, Gomez JE
-
Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study
Hereditary Cancer in Clinical Practice, 2020
2020Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N
-
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
Cancer, 2020
2020Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD
-
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
American Journal of Hematology, 2019
2019Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB
-
Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer
Future Oncology, 2019
2019Bobbili P, Ryan K, Duh MS, Dua A, Fernandes AW, Pavilack M, Gomez JE
-
Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans
Clinical Therapeutics. 2018 Sep;40(9):1496-1508
2018DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y
-
Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets
Current Medical Research and Opinion. Apr 27 2018:1-14
2018Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M
-
December 4, 2024
-
April 9, 2024
-
June 27, 2023
-
August 17, 2022
